Scienture Holdings, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Scienture Holdings, Inc. (NASDAQ:SCNX) operates as a holding company for pharmaceutical operating companies focused on developing, commercializing, and distributing novel specialty pharmaceutical products to address unmet needs in central nervous system and cardiovascular diseases in the United States. The company conducts operations through its Scienture, LLC subsidiary, which researches and develops branded products including SCN-102, an oral liquid formulation of losartan potassium in phase 1 for hypertension, diabetic nephropathy, and stroke risk reduction; SCN-104, a multi-dose dihydroergotamine mesylate injection pen for acute migraine treatment; SCN-106, a thrombolytic agent for thrombosis; and SCN-107, a long-acting non-opioid analgesic injection for postsurgical pain; through Integra Pharma Solutions for wholesale of licensed pharmaceutical brands, generics, and non-drug products; and previously through divested healthcare IT and wholesale units. Products target patients, physicians, caregivers, hospitals, clinics, and pharmacies across therapeutic areas such as hypertension, migraine, pain, and thrombosis, with geographic focus in the United States; founded in 2010 and headquartered in Tampa, Florida. In September 2024, the company rebranded from TRxADE Health, Inc., changed its ticker from MEDS to SCNX, and completed a business combination with Scienture, Inc. valued at $103 million; in Q1 2024 sold TRxADE Inc. assets for $22.5 million; in April 2025 divested legacy subsidiaries Integra Pharma Solutions, Bonum Health, and Softell to Tollo Health for $5 million to streamline as a pure-play specialty pharma entity; secured $1.2 million in bridge funding toward $3 million in July 2025 and priced a $3.9 million registered direct offering; launched Arbli (losartan potassium) as the first FDA-approved ready-to-use liquid available via major U.S. wholesalers, with multiple GPO agreements and PBM-led rebate deals expanding access to over 2,500 institutions in the $256 million losartan market; and fully repaid outstanding debentures to strengthen its balance sheet.
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
Scienture (SCNX) Projected to Post Earnings on Tuesday
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Scienture Holdings, Inc. (NASDAQ:SCNX) Sees Significant Growth in Short Interest
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA